Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Carter

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
Cancer Research|October 27, 1997
2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenograftsD Marcantonio, L C Panasci, M G Hollingshead, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2013
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerR J Kelly, A Thomas, A Rajan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancerC A Carter, A Rajan, C Keen, et al.
International Angiology : a Journal of the International Union of Angiology|March 31, 2010
A consensus conference on complex biologics and low molecular weight heparinsE Kalodiki, J Fareed, V F Tapson, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
Cancer Research|October 27, 1997
2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenograftsD Marcantonio, L C Panasci, M G Hollingshead, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2013
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerR J Kelly, A Thomas, A Rajan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancerC A Carter, A Rajan, C Keen, et al.
International Angiology : a Journal of the International Union of Angiology|March 31, 2010
A consensus conference on complex biologics and low molecular weight heparinsE Kalodiki, J Fareed, V F Tapson, et al.
Pageof 11